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Abstract
Background
Renal dysfunction and anaemia are common in patients with acute heart failure (HF). It is
not known whether their combined presence has additive prognostic value. We investigated
their prognostic value separately and in combination, on prognosis in acute HF patients.
Furthermore, we examined whether the improvement in prognosis was comparable
between patients with and without renal dysfunction.
Methods and results
This prospective registry includes 1783 patients admitted to the (Intensive) Coronary Care
Unit for acute HF in the period of 1985–2008. The outcome measure was the composite of
all-cause mortality, heart transplantation and left ventricular assist device implantation. In
patients without renal dysfunction, anemia was associated with worse 30-day outcome (HR
2.91; [95% CI 1.69–5.00]), but not with 10-year outcome (HR 1.13 [95% CI 0.93–1.37]). On
the contrary, anemia was found to influence prognosis in patients with renal dysfunction,
both at 30 days (HR 1.93 [95% CI 1.33–2.80]) and at 10 years (HR 1.27 [95% CI 1.10–
1.47]). Over time, the 10-year survival rate improved in patients with preserved renal func-
tion (HR 0.73 [95% CI 0.55–0.97]), but not in patients with renal dysfunction.
Conclusion
The long-term prognosis of acute HF patients with a preserved renal function was found to
have improved significantly. However, the prognosis of patients with renal dysfunction did
not change. Anemia was a strong prognosticator for short-term outcome in all patients. In
patients with renal dysfunction, anemia was also associated with impaired long-term
prognosis.
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Introduction
Acute heart failure (HF) is commonly accompanied by various non-cardiovascular comorbidi-
ties. Renal dysfunction is among one of the most common although its exact prevalence has
varied between studies.[1, 2] Renal dysfunction in acute HF is associated with various adverse
outcomes: longer hospital stay, higher re-hospitalization rate, and higher mortality.[1, 2] Of
note, the follow-up period in most of these studies is restricted to only 1 year after the initial
hospitalization.
In the last decades, an improvement in long-term outcome has been observed among
patients with acute HF in several cohorts.[3–5] New therapeutic options and an increased
understanding of the pathophysiology of HF are most likely responsible for this trend. Impor-
tantly, renal dysfunction is a (relative) contra-indication for some of the new therapeutic
modalities[6]. As of yet, it has not been established whether the improvement in prognosis
over time of patients with acute HF is modified by the presence of renal dysfunction.
Anemia is another important and common comorbidity in patients with acute HF, with a
prevalence up to almost 60%.[7–12] There is conflicting data regarding the prognostic impact
of anemia in patients with acute HF.[10–13] Moreover, the combination of HF, renal dysfunc-
tion and anemia carries an incremental negative prognostic impact in patients with chronic
HF.[14] However, the additive prognostic value of anemia in patients with acute HF with and
without renal dysfunction remains scarce.
Therefore, the aims of the present study were (1) to examine the impact of renal function
on short- and long-term prognosis of patients with acute HF, (2) to determine whether the
improvement in prognosis of patients with acute HF and renal impairment was comparable to
that of patients with normal renal function, and (3) to study the impact of anemia, alone or in
combination with renal dysfunction, on prognosis of patients with acute HF.
Materials and methods
Patients
This prospective registry was carried out among patients who were admitted with acute HF at
the Intensive Coronary Care Unit (ICCU) in our hospital during the period from 1985 until
2008. The study design and inclusion have been described previously.[5] Briefly, consecutive
patients aged 18 years and older were included when they were diagnosed with acute HF or
cardiogenic shock at admission. Both patients with de novo HF and patients with worsening
symptoms of chronic HF were included. Patients could only contribute once to the database,
and if patients were admitted more than once with acute HF during the inclusion period, only
the first admission was included for analyses.
This was a prospective cohort registry. For analyses, we used completely anonymized data.
During the enrolment of the patients, approval from the research ethics committee of the Eras-
mus MC to conduct this study was not required. At a later stage, the committee confirmed
that we did not need their approval to conduct this study. Furthermore, there was no require-
ment for patients’ informed consent. The study was conducted according to the Declaration of
Helsinki.[15]
Endpoints
The outcome measure was the composite of all-cause mortality, heart transplantation and left
ventricular assist device (LVAD) implantation at 30 days, 1 year and 10 years after the initial
hospitalization.
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Survival status was assessed by using the Municipal Civil Registries in January 2017 and was
available for 98% of the included patients. To determine whether patients received an LVAD
or underwent heart transplantation, we used prospectively collected data from our hospital
information system.
Variables and definitions
Baseline variables were derived from patient records and discharge letters. We collected the
following variables: age, gender, Body Mass Index (BMI), cardiac history, etiology of HF, left
ventricular ejection fraction (LVEF) and treatment at the ICCU. Furthermore, the results of
the following laboratory tests were collected: sodium (mmol/L), potassium (mmol/L), creati-
nine (μmol/L), urea (mmol/L) and hemoglobin (mmol/L).
Diabetes mellitus was considered to be present when patients received antidiabetic therapy.
The LVEF was classified into the following qualitative categories: good, moderate and poor. If
quantitative outcome for the LVEF was used, we applied the following cut-offs: >45%, 30–
44% and<30% for good, moderate and poor LVEF, respectively.[5] The etiology of HF was
categorized into ischemic cause versus non-ischemic cause of HF. For all laboratory tests, the
first measured value during hospitalization was taken into account. The estimated glomerular
filtration rate (eGFR) was estimated by using the Modification of Diet in Renal Disease
(MDRD) equation for serum creatinine (μmol/L): eGFR = 30849 × serum creatinine −1.154 ×
age −0.203 × 0.742 (if female) [eGFR in mL/min/1.73 m2].[16] In line with the most recent HF
guideline of the European Society of Cardiology,[6] renal function was categorized as follows:
preserved renal function: eGFR60 mL/min/1.73 m2; moderately impaired renal function
eGFR 30–59 mL/min/1.73 m2; severely impaired renal function eGFR<30 mL/min/1.73 m2.
We used the definition of the World Health Organization to define anemia: hemoglobin <7.5
mmol/L in women and <8.2 mmol/L in men. Hyponatremia was defined as a serum sodium
level135 mmol/L. For the definition of hypo- and hyperkalemia the following cut-off values
were applied: serum potassium <3.5 mmol/L and>5.0 mmol/L, respectively.
Statistical analysis
Categorical variables are presented as frequencies and percentages. The χ2 test and the Fisher-
Freeman-Halton exact test were used to compare categorical variables. Normally distributed,
continuous data are presented as mean values with standard deviation and were compared
using the one-way ANOVA. Continuous data that were not normally distributed are presented
as median and interquartile range (IQR). The Mann-Whitney U test or the Kruskal-Wallis H
test was used to compare these data.
Since data for LVEF and etiology were incomplete for, respectively, 28% and 12% of the
patients, multiple imputation was performed by using baseline characteristics as predictors.
Pooled means are given for LVEF and etiology.
The Kaplan-Meier method was used for presenting the cumulative event curves and they
were compared using the log-rank test. Secondary analyses were carried out among the 30-day
event-free survivors. Logistic regression for 30-day outcome and the Cox proportional hazard
method for long-term outcome were applied in order to examine the independent association
between renal function and the composite endpoint of all-cause mortality, heart transplanta-
tion and LVAD implantation, as well as between anemia and the composite endpoint. Adjust-
ments were made for age, gender, history of HF, diabetes, hypertension, etiology of HF, atrial
fibrillation at admission, LVEF, renal function and anemia.
All tests were two-tailed and p-values <0.05 were considered statistically significant. Results
of logistic regression and the Cox proportional hazard model were reported as odds ratios
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(ORs) and hazard ratios (HRs), respectively, with their corresponding 95% confidence interval
(95% CI). All statistical analyses were carried out using SPSS software (SPSS 21.0, IBM Corp.,
Armonk, NY, USA).
Results
Baseline characteristics
In total, 1810 patients were admitted with acute HF in the period 1985–2008. Of these, 1783
(99%) patients had at least one creatinine measurement and they constitute the present study
population. Over half of the patients were found to have renal dysfunction, which was severely
impaired in 18%. The proportion of patients with severe renal impairment remained stable
over time, whereas the number of patients with preserved renal function increased and moder-
ately impaired renal function became less prevalent (p<0.001; Fig 1).
Compared to patients with renal dysfunction, patients with preserved renal function were
on average 6 years younger (Table 1). In addition, they less often had prior myocardial infarc-
tion and coronary revascularization. With decreasing renal function, the prevalence of prior
HF, diabetes and hypertension increased. Hyponatremia was also more common in patients
with renal dysfunction, as was anemia.
Regarding therapy, patients with renal impairment were more frequently treated with intu-
bation and mechanical ventilation, mechanical circulatory support and inotropic agents
(Table 1). Moreover, the degree of renal impairment was associated with lower in-hospital
usage of beta-blockers, ACE-inhibitors and diuretics.
Renal function and outcome
The median survival of patients with a severely impaired, moderately impaired and preserved
renal function was 1.0, 2.1 and 4.4 years, respectively. The impact of renal function on outcome
is shown in Fig 2 and Table 2. Patients with a severely impaired renal function had the worst
prognosis both at short- and long-term. These findings remained unchanged after multivari-
able adjustment for other prognostic factors. Although the influence of renal function on prog-
nosis became less prominent with longer duration of follow-up, renal function still remained a
Fig 1. Distribution of the study population according to the renal function and the admission period. eGFR,
estimated glomerular filtration rate in mL/min/1.73 m2.
https://doi.org/10.1371/journal.pone.0201714.g001
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Table 1. Baseline characteristics and therapy according to renal function.
eGFR60 eGFR 30–59 eGFR <30 p-value
No. of patients 688 (39%) 778 (44%) 317 (18%)
Baseline
Age (mean, y) 59.7 ± 16.3 66.1 ± 13.2 65.9 ± 12.9 <0.001
Male 458 (67%) 475 (61%) 201 (63%) 0.09
BMI 25.4 ± 5.2 24.9 ± 4.8 25.0 ± 4.7 0.57
Medical history
Myocardial infarction 237 (34%) 347 (45%) 120 (38%) <0.001
Coronary revascularization† 124 (18%) 187 (24%) 75 (24%) 0.01
Heart surgery (not CABG) 111 (16%) 87 (11%) 36 (11%) 0.01
Heart transplantation 2 (0.3%) 1 (0.1%) 6 (2%) 0.002
Waiting for heart transplantation 16 (2.3%) 11 (1.4%) 8 (2.5%) 0.33
Heart failure 300 (44%) 390 (50%) 188 (59%) <0.001
Rhythm- or conduction disorder 157 (23%) 210 (27%) 73 (23%) 0.14
Diabetes 132 (19%) 168 (22%) 81 (26%) 0.07
Hypertension 194 (28%) 257 (33%) 133 (42%) <0.001
Heart failure
Etiology of heart failure <0.05
Ischemic origin 302 (44%) 392 (50%) 140 (44%)
Non-ischemic origin 386 (56%) 386 (50%) 177 (56%)
Atrial fibrillation at admission 159 (23%) 178 (23%) 49 (16%) 0.01
Left ventricular ejection fraction <0.05
Good 199 (29%) 225 (29%) 91 (29%)
Moderate 187 (27%) 156 (20%) 76 (24%)
Poor 302 (44%) 396 (51%) 149 (47%)
Laboratory values
Sodium 137 ± 5 137 ± 6 135 ± 6 <0.001
Potassium 4.0 ± 0.6 4.2 ± 0.7 4.6 ± 0.9 <0.001
Urea (median, IQR) 7.2 (5.7–9.3) 10.6 (8.2–14.4) 23.5 (17.5–30.8) <0.001
eGFR (median, IQR) 75 (66–89) 47 (39–53) 20 (14–25) <0.001
Creatinine (median, IQR) 80 (71–96) 123 (109–142) 258 (215–346) <0.001
Hemoglobin 8.3 ± 1.3 8.1 ± 1.4 6.9 ± 1.5 <0.001
Hyponatremia 221 (32%) 224 (29%) 151 (48%) <0.001
Hypokalemia 106 (15%) 98 (13%) 23 (7%) <0.001
Hyperkalemia 38 (6%) 81 (10%) 85 (27%) <0.001
Anemia 262 (38%) 334 (43%) 244 (77%) <0.001
Therapy during ICCU hospitalization
Intubation 69 (10%) 117 (15%) 57 (18%) 0.001
Resuscitation 19 (3%) 36 (5%) 15 (5%) 0.13
Mechanical circulatory support‡ 34 (5%) 41 (5%) 29 (9%) 0.02
Inotropics 196 (29%) 253 (33%) 123 (39%) 0.01
Beta-blocker 146 (21%) 111 (14%) 47 (15%) 0.001
Antiarrhythmics 115 (17%) 154 (20%) 45 (14%) 0.06
Calcium antagonist 77 (11%) 102 (13%) 72 (23%) <0.001
Digitalis 300 (44%) 347 (45%) 87 (27%) <0.001
ACE-inhibitor or ARB 422 (61%) 430 (55%) 113 (36%) <0.001
Diuretics 640 (93%) 718 (92%) 257 (81%) <0.001
Nitrates 234 (34%) 289 (37%) 121 (38%) 0.24
(Continued)
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strong predictor of the composite endpoint of all-cause mortality, heart transplantation and
LVAD implantation.
Over time, the 10-year outcome of patients with a preserved renal function improved signif-
icantly, both unadjusted (HR 0.70 [95% CI 0.61–0.81] for most recent period versus first
period) and after adjustment for confounding variables (adjusted HR 0.73 [95% CI 0.55–0.97];
Fig 3A). This improvement was more pronounced among the 30-day survivors (adjusted HR
0.65 [95% CI 0.48–0.88]; Fig 3B). In contrast, this pattern was not present in patients with
renal dysfunction. Consequently, the prognosis of these patients did not improve over time.
Anemia and outcome
Almost 50% of the patients were found to have anemia. The characteristics of these patients
differed in some aspects from those without anemia (Table 3). Anemic patients more fre-
quently had previous HF and atrial fibrillation at admission. Importantly, they more often had
impaired renal function.
Table 1. (Continued)
eGFR60 eGFR 30–59 eGFR <30 p-value
Nitroprusside 46 (7%) 74 (10%) 39 (12%) 0.01
Antiplatelet agents 200 (29%) 189 (24%) 71 (22%) 0.04
Oral anticoagulant 351 (51%) 406 (52%) 136 (43%) 0.02
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass Index; CABG, coronary artery bypass graft; eGFR, estimated glomerular
filtration rate; ICCU, intensive cardiac care unit; IQR, interquartile range
p for any difference
†Percutaneous coronary intervention and/or CABG
‡Intra-aortic balloon pump and/or left ventricular assist device and/or extracorporeal membrane oxygenation
https://doi.org/10.1371/journal.pone.0201714.t001
Fig 2. Kaplan-Meier curve of patients with acute heart failure according to the renal function. eGFR, estimated
glomerular filtration rate in mL/min/1.73 m2; LVAD, left ventricular assist device.
https://doi.org/10.1371/journal.pone.0201714.g002
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The prognosis of patients with anemia was worse than of patients without anemia (Fig 4).
After adjustment for confounders, anemia remained significantly associated with increased for
reaching the composite endpoint of all-cause mortality, heart transplantation and LVAD
implantation at 30 days, 1 year and 10 years (HR 2.23 [95% CI 1.64–3.03], HR 1.58 [95% CI
1.33–1.87] and HR 1.24 [1.11–1.39], respectively; Table 4).
Since anemia was a predictor of poor outcome in the total population of acute HF patients,
we separately analyzed whether anemia had incremental prognostic value independent from
renal dysfunction (Fig 5). Among patients with a preserved renal function, anemia proved to
be a strong predictor for 30-day outcome, but its prognostic value decreased with longer dura-
tion of follow-up. In contrast, anemia was associated with worse outcome both during short-
and long-term follow-up among patients with renal dysfunction. This relationship persisted
after the exclusion of patients who died within 30 days after admission.
Discussion
In this prospective registry of patients with acute HF, we found that renal dysfunction was a
strong predictor for poor outcome (i.e. the composite of all-cause mortality, heart transplanta-
tion and LVAD implantation) up to 10 years following initial hospitalization. Importantly, this
study is the first to show that patients with acute HF and an impaired renal function had no
improvement in prognosis that occurred in the last three decades. This contrasts findings in
patients with a preserved renal function. Furthermore, we found that the prognostic impact of
anemia was dependent on the presence of renal function. Anemia had no impact on the long-
term prognosis of patients with a preserved renal function. On the other hand, anemia was
associated with impaired prognosis among patients with renal dysfunction.
Renal function and prognosis
Renal dysfunction proved to be a strong predictor of a poor outcome: the poorer the renal
function, the poorer the prognosis. Among studies that demonstrated the adverse association
between renal dysfunction and poor survival,[1, 2] most only used a short follow-up period,
usually up to 1 year after hospitalization. Our results support and extend these findings by
Table 2. Prognosis at different follow-up moments according to renal function.
All-cause mortality, heart transplantation or LVAD implantation Univariable analysis Multivariable analysis
30 days
eGFR60 10% Reference Reference
eGFR 30–59 14% 1.51 (1.10–2.08) 1.50 (1.06–2.11)
eGFR <30 24% 2.85 (1.99–4.08) 2.32 (1.55–3.47)
1 year
eGFR60 28% Reference Reference
eGFR 30–59 36% 1.41 (1.17–1.69) 1.34 (1.11–1.62)
eGFR <30 50% 2.21 (1.79–2.73) 1.81 (1.44–2.28)
10 years
eGFR60 69% Reference Reference
eGFR 30–59 81% 1.42 (1.33–1.51) 1.24 (1.09–1.40)
eGFR <30 92% 2.14 (1.99–2.31) 1.68 (1.43–1.96)
eGFR, estimated glomerular filtration rate in mL/min/1.73 m2; LVAD, left ventricular assist device
Odds ratio with 95% confidence interval (CI) for 30-day outcome, hazard ratio with 95% CI for 1-year and 10-year outcome
https://doi.org/10.1371/journal.pone.0201714.t002
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demonstrating that renal dysfunction continued to be a strong predictor for long-term out-
come (i.e. 10 years).
Fig 3. Prognosis over time among (A) the total population and (B) the 30-day survivors of patients with acute heart failure. Results were
divided into three groups according to the renal function. CI, confidence interval; eGFR, estimated glomerular filtration rate in mL/min/1.73 m2;
HR, hazard ratio.
https://doi.org/10.1371/journal.pone.0201714.g003
Renal function, anemia and acute HF outcome
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Table 3. Baseline characteristics and therapy of patients with and without anemia.
Anemia + Anemia - p-value
No. of patients 850 (48%) 919 (52%)
Baseline
Age (mean, y) 63.1 ± 14.5 64.1 ± 15.0 0.15
Male 565 (67%) 560 (61%) 0.02
BMI 24.8 ± 4.8 25.4 ± 5.2 0.20
Medical history
Myocardial infarction 336 (40%) 362 (39%) 0.95
Coronary revascularization 199 (23%) 183 (20%) 0.07
Heart surgery (not CABG) 131 (15%) 102 (11%) 0.01
Heart transplantation 8 (0.9%) 1 (0.1%) 0.02
Waiting for heart transplantation 22 (2.6%) 12 (1.3%) 0.05
Heart failure 440 (52%) 425 (46%) 0.02
Rhythm- or conduction disorder 215 (25%) 218 (24%) 0.44
Diabetes 199 (23%) 181 (20%) 0.06
Hypertension 271 (32%) 308 (34%) 0.47
Heart failure
Etiology of heart failure >0.05
Ischemic origin 387 (45%) 438 (48%)
Non-ischemic origin 463 (55%) 481 (52%)
Atrial fibrillation at admission 141 (17%) 243 (26%) <0.001
Left ventricular ejection fraction >0.05
Good 260 (31%) 250 (27%)
Moderate 192 (23%) 227 (25%)
Poor 399 (47%) 442 (48%)
Laboratory values
Sodium 136 ± 6 138 ± 5 <0.001
Potassium 4.3 ± 0.8 4.1 ± 0.7 0.001
Urea (median, IQR) 12.6 (8.3–20.4) 8.4 (6.6–11.6) <0.001
eGFR (median, IQR) 47 (26–64) 57 (43–73) <0.001
Creatinine (median, IQR) 123 (94–200) 102 (82–130) <0.001
Hemoglobin 6.7 ± 0.9 9.0 ± 0.8 <0.001
Hyponatremia 359 (42%) 233 (25%) <0.001
Hypokalemia 100 (12%) 125 (14%) 0.28
Hyperkalemia 122 (14%) 85 (9%) 0.001
Therapy during ICCU hospitalization
Intubation 151 (18%) 92 (10%) <0.001
Resuscitation 36 (4%) 34 (4%) 0.56
Mechanical circulatory support† 80 (9%) 23 (3%) <0.001
Inotropics 329 (39%) 238 (26%) <0.001
Beta-blocker 128 (15%) 174 (19%) 0.03
Antiarrhythmics 143 (17%) 165 (18%) 0.53
Calcium antagonist 130 (15%) 123 (13%) 0.25
Digitalis 305 (36%) 419 (46%) <0.001
ACE-inhibitor or ARB 417 (49%) 540 (59%) <0.001
Diuretics 747 (88%) 854 (93%) <0.001
Nitrates 295 (35%) 342 (37%) 0.27
Nitroprusside 73 (9%) 86 (9%) 0.57
(Continued)
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It is generally assumed that the new therapeutic options for the treatment of HF developed
during the last decades are responsible for the prognostic improvement in the total population
of patients acute HF. Our finding that only patients with a normal renal function experienced
an improved long-term prognosis in the most recently study period is novel. This contrasts
with the findings currently obtained among patients with renal dysfunction. Their prognosis
remained stable over time. So far, the temporal trends in prognosis have not been studied sepa-
rately for patients with and without renal dysfunction. Two potential mechanisms may explain
this finding. First, some of the new therapeutics, like ACE inhibitors, ARBs and MRAs, that
are considered to be responsible for the prognostic improvement of patients with HF over the
last decades, interact with the renal function.[6] Moreover, patients with lower eGFR were also
less frequently treated with diuretics during ICCU admission. Therefore, it is plausible that
patients with renal dysfunction were less frequently treated with these drugs and that, in case
they were treated, the optimal dose was not achieved. Indeed, we found that ACE inhibitors
were less frequently prescribed during admission in patients with renal dysfunction. Although
data on medical therapy during follow-up were not included in this registry, it can be assumed
that this pattern of prescription continued after discharge. Another possible explanation for
the disparity in temporal trends between patients with and without renal dysfunction may be
the grade of their illness. Patients with renal dysfunction had more comorbidities and were
Table 3. (Continued)
Anemia + Anemia - p-value
Antiplatelet agents 238 (28%) 224 (24%) 0.08
Oral anticoagulant 383 (45%) 497 (54%) <0.001
ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; BMI, Body Mass Index; CABG, coronary artery bypass graft; eGFR, estimated glomerular
filtration rate; ICCU, intensive cardiac care unit; IQR, interquartile range
Percutaneous coronary intervention and/or CABG
†Intra-aortic balloon pump and/or left ventricular assist device and/or extracorporeal membrane oxygenation
https://doi.org/10.1371/journal.pone.0201714.t003
Fig 4. Kaplan-Meier curve of acute heart failure patients with and without anemia. LVAD, left ventricular assist
device.
https://doi.org/10.1371/journal.pone.0201714.g004
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more frequently treated with intubation, mechanical circulatory support and inotropics than
patients with preserved renal function. This suggests that patients with renal dysfunction were
more critically ill as compared to those with a preserved renal function, and they might thus
experience a more progressive course of their disease and, therefore, a poorer prognosis.
Table 4. Prognosis at different follow-up moments according to the presence of anemia.
All-cause mortality, heart transplantation or LVAD implantation Univariable analysis Multivariable analysis
30 days
No anemia 9% Reference Reference
Anemia 20% 2.55 (1.92–3.38) 2.23 (1.64–3.03)
1 year
No anemia 28% Reference Reference
Anemia 43% 1.75 (1.49–2.05) 1.58 (1.33–1.87)
10 years
No anemia 75% Reference Reference
Anemia 83% 1.35 (1.28–1.43) 1.24 (1.11–1.39)
LVAD, left ventricular assist device
 Odds ratio with 95% confidence interval (CI) for 30-day outcome, hazard ratio with 95% CI for 1-year and 10-year outcome
https://doi.org/10.1371/journal.pone.0201714.t004
Fig 5. Prognostic impact of anemia at different follow-up moments in the total population and 30-day survivors. Analyses were
separately done for renal impairment whether or not. CI, confidence interval; eGFR, estimated glomerular filtration rate in mL/min/1.73
m2; HR, hazard ratio; outcome at 30 days was reported as odds ratio with 95% CI.
https://doi.org/10.1371/journal.pone.0201714.g005
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Anemia and prognosis
The second result of our study was the finding that anemia was associated with both an
impaired short- and long-term prognosis among patients with acute HF. The relation between
anemia and adverse outcome in patients with acute HF has been published previously,
although the data are not consistent.[10–13] Two studies that did not report anemia to be a
prognosticator of poor outcome had study populations with quite different characteristics
than ours.[10, 13]
When we studied the prognostic value of anemia in more detail, we found that anemia was
an independent predictor of short-term outcome in all patients, irrespective of renal function.
However, while anemia also was independently associated with an impaired outcome during
long-term follow-up in patients with renal dysfunction, its presence had no incremental long-
term prognostic impact in patients with a preserved renal function. The reasons for this differ-
ence are not totally clear. A possible explanation may be the actual cause of the anemia. How-
ever, as we were not able to assess the exact etiology of the anemia, the following hypothesis
should be studied further in the future.
Anemia in patients with HF is well known, and has been attributed to multiple factors
including iron deficiency, renal dysfunction, HF as a chronic disease and hemodilution.[14]
The iron status was not assessed in our patients so we cannot make any conclusions as whether
there was a difference in iron status between patients with and without renal dysfunction. The
fact that anemia was associated with impaired long-term outcome in patients with renal dys-
function but not in patients with a preserved renal function might be due to the fact that
patients with renal dysfunction more frequently had ‘true anemia’.
Hemodilution is one of the potential causes of anemia in patients with HF.[17] The causal
factor in that case is a low hemoglobin level caused by an increased extracellular volume.
When the extracellular volume decreases, for example by diuretic therapy, the hemoglobin
level will increase and the patient will no longer be classified as having anemia. Therefore, in
case of hemodilution anemia should be seen as a marker of fluid retention, just as sodium
level. We hypothesize that hemodilution as the only cause of anemia was more frequent in
patients without renal dysfunction than in those with renal dysfunction. Probably, patients
with an impaired renal function had also anemia based on hemodilution but in addition,
could also have suffered from ‘true anemia’. There are several reasons for such a phenomenon.
First, it is well known that renal failure is associated with anemia.[14] Second, in our study,
chronic HF was more common among patients with renal dysfunction than among those
without renal dysfunction. Since chronic HF has been associated with elevated plasma levels of
cytokines,[18] chronic HF can cause anemia of chronic diseases. These cytokines suppress the
erythropoietic stem cells in the bone marrow and reduce the release of iron form the reticulo-
endothelial system, resulting in anemia.[19]
The so-called cardiorenal anemia syndrome has not been investigated extensively in
patients with acute HF. Investigators form the ATTEND registry also found anemia to be a
strong predictor of in-hospital mortality both among patients with and without renal dysfunc-
tion.[20] Furthermore, their results with respect to the 1-year outcome were consistent with
our data. In addition, these authors also showed that anemia had additive prognostic value for
increased 1-year mortality only in the patients with renal dysfunction but not in those with a
preserved renal function.[21] Because these investigators used anemia at discharge as predic-
tor, and thus made hemodilution less likely as cause from anemia, this supports our hypothesis
of ‘true anemia’ among patients with renal dysfunction. Our data provide new evidence on the
very long-term prognosis of patients with acute HF since we found that anemia, even after 10
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years of follow-up, continued to have additive prognostic value among patients with renal
dysfunction.
Strengths and limitations
The unique strength of our study is the duration of the follow-up of 10 years after the initial
hospitalization. This enabled us to investigate the prognostic impact of renal dysfunction, ane-
mia, as well as their interrelationship on short- en (very) long-term. Research covering three
decades with such a long follow-up time is quite unique in this research field.
Despite these strengths, some limitations should be considered in the interpretation of the
results of this study. Since our study was done in a tertiary referral hospital, external validity
could have been affected. However, despite the fact that our hospital was a tertiary referral cen-
ter, a significant part of our patients still were primary and secondary referrals. Therefore, our
population consisted of patients within the whole, broad range of patients admitted with acute
HF. Second, analyses were made on a composite outcome and therefore caution is needed
when interpreting the estimates of the covariates, since these are estimates on the composite
outcome only and not on the separate outcomes. Third, we were not able to identify the cause
of anemia in all patients, nor were we always able to assess whether patients had chronic or
acute renal dysfunction. Furthermore, while it has been suggested that changing hemoglobin
and creatinine levels during admission may influence prognosis,[2, 22] the design of our study
did not allow us to assess trends in hemoglobin and creatinine levels. Finally, since we had no
data on the ethnicity of our patients, we could not multiply for black race in the MDRD for-
mula. Therefore, the eGFR that we employed might be an underestimation of the real renal
function. However, such misclassification could have only led to underestimation of the effects
observed.
Conclusions
We found renal dysfunction to be a strong predictor of both short- and long-term composite
endpoint of all-cause mortality, heart transplantation and LVAD implantation among patients
with acute HF. In addition, we established that the long-term prognosis of patients with a pre-
served renal function significantly improved over the last decades. However, in patients with
renal dysfunction, the prognosis did not improve over the last decades. These findings empha-
size the importance of renal dysfunction as comorbidity in patients with HF and underscore
the need for new therapeutic modalities, especially for patients with renal dysfunction. Fur-
thermore, we established anemia as a prognosticator of short-term outcome both among acute
HF patients with and without renal dysfunction. Among patients with renal dysfunction, the
presence of anemia was also associated with impaired long-term prognosis. Anemia did not
influence the long-term prognosis of patients with preserved renal function. Further research
should be undertaken to investigate the pathogenesis of the prognostic impact of anemia and
renal dysfunction among patients with acute HF.
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